Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Go back to Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting| (NASDAQ: CVKD) | Delayed: 3.10 -0.06 (1.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.16 | 52 Week High | $ | |||
| Open | $3.14 | 52 Week Low | $ | |||
| Day High | $3.30 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $ | |||
| Volume | 62,869 | |||||
